|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM369794494 |
| 003 |
DE-627 |
| 005 |
20240704232011.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240316s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202311283
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1460.xml
|
| 035 |
|
|
|a (DE-627)NLM369794494
|
| 035 |
|
|
|a (NLM)38489768
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kim, Dohyeon
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Glycocalyx-Mimicking Nanoparticles with Differential Organ Selectivity for Drug Delivery and Therapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.07.2024
|
| 500 |
|
|
|a Date Revised 04.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Organ-selective drug delivery is expected to maximize the efficacy of various therapeutic modalities while minimizing their systemic toxicity. Lipid nanoparticles and polymersomes can direct the organ-selective delivery of mRNAs or gene editing machineries, but their delivery is limited to mostly liver, spleen, and lung. A platform that enables delivery to these and other target organs is urgently needed. Here, a library of glycocalyx-mimicking nanoparticles (GlyNPs) comprising five randomly combined sugar moieties is generated, and direct in vivo library screening is used to identify GlyNPs with preferential biodistribution in liver, spleen, lung, kidneys, heart, and brain. Each organ-targeting GlyNP hit show cellular tropism within the organ. Liver, kidney, and spleen-targeting GlyNP hits equipped with therapeutics effectively can alleviate the symptoms of acetaminophen-induced liver injury, cisplatin-induced kidney injury, and immune thrombocytopenia in mice, respectively. Furthermore, the differential organ targeting of GlyNP hits is influenced not by the protein corona but by the sugar moieties displayed on their surface. It is envisioned that the GlyNP-based platform may enable the organ- and cell-targeted delivery of therapeutic cargoes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a bilirubin
|
| 650 |
|
4 |
|a bilirubin nanoparticles
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a glycocalyx
|
| 650 |
|
4 |
|a glyconanoparticles
|
| 650 |
|
4 |
|a organ tropism
|
| 650 |
|
7 |
|a Acetaminophen
|2 NLM
|
| 650 |
|
7 |
|a 362O9ITL9D
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 700 |
1 |
|
|a Whang, Chang-Hee
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hong, Jungwoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Prayogo, Monica Celine
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jung, Wonsik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Seojung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shin, Hocheol
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Yujin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Jiyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Min Joong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Kyunggon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Hee-Seung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jon, Sangyong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 27 vom: 28. Juli, Seite e2311283
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:27
|g day:28
|g month:07
|g pages:e2311283
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202311283
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 27
|b 28
|c 07
|h e2311283
|